EagleClaw Capital Management’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.31M Buy
67,845
+35,098
+107% +$2.83M 0.71% 46
2026
Q1
$2.84M Buy
32,747
+600
+2% +$57.5K 0.4% 63
2025
Q4
$3.09M Sell
32,147
-200
-0.6% -$19.4K 0.45% 61
2025
Q3
$3.08M Buy
32,347
+100
+0.3% +$9.19K 0.43% 58
2025
Q2
$2.81M Buy
32,247
+2,037
+7% +$173K 0.42% 61
2025
Q1
$2.71M Buy
30,210
+1,588
+6% +$142K 0.43% 67
2024
Q4
$2.29M Buy
28,622
+100
+0.4% +$8.66K 0.36% 71
2024
Q3
$2.57M Buy
28,522
+2,487
+10% +$209K 0.43% 68
2024
Q2
$2.05M Buy
26,035
+725
+3% +$59.4K 0.37% 73
2024
Q1
$2.21M Buy
+25,310
New +$2.16M 0.4% 71

Other funds holding MDT

EagleClaw Capital Management's MDT Position: Q2 2026 in Review

EagleClaw Capital Management increased its Medtronic (MDT) stake by 107% in Q2 2026, buying an estimated $2.83M and bringing the position to 67,845 shares worth $5.31M. The position accounts for 0.71% of the portfolio, ranked #46.

EagleClaw Capital Management first reported a position in MDT in Q1 2024 and has held it in 10 quarters since. 2,125 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • EagleClaw Capital Management held 67,845 shares of Medtronic worth $5.31M as of Q2 2026.
  • EagleClaw Capital Management bought 35,098 Medtronic shares in Q2 2026, an estimated $2.83M.
  • Medtronic made up 0.71% of EagleClaw Capital Management's portfolio in Q2 2026, its #46 holding.
  • EagleClaw Capital Management first reported a position in Medtronic in Q1 2024 and has held it in 10 quarters since.
  • 2,125 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on EagleClaw Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.